Henlius
Shanghai Henlius Biotech is joint venture company that provides clinical-stage biopharmaceutical services.
Henlius, founded in February, 2010 and headquartered in Shanghai, is a medical company involved in tumors and autoimmune diseases. The founder is Chen Qiyu. Listed on the HKEX on September 25, 2019, the company's major shareholders are Shanghai Fosun New Medicine Research Co., Ltd., Henlius Biopharmaceuticals Inc. and Shanghai Fosun Pharmaceutical Industry Development Co., Ltd. Rivals that have direct and indirect competition with Henlius include Kintor, HitGen, Aprea Therapeutics, BridgeBio Pharma, etc.
AI Pharmaceutical R&D Company DP Technology Raises New Round of Over CNY 700 Mn Financing
EqualOcean has learned that DP Technology(深势科技), an AI pharmaceutical research company, has recently successfully completed a funding round of over CNY 700 million. Investors in this round include Zhongyuan Capital(众源资本), MSA Capital(和玉资本), Loyal Valley Capital(正心谷资本), Evergreen Scitech Delta(深势科技), and many other industry-specific investors, with Lighthouse Capital(光源资本) serving as the exclusive financial advisor.
Aug 22, 2023 03:34 PM